RxDoctor Payments Data

Ikenna Nwosu, MD

Family Medicine · Fresno, CANPI 1629604574

Payments from drug & device makers

$1,954in general payments, 2019–2025

Across 69 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$498
  • Regeneron Healthcare Solutions, Inc.$340
  • Sanofi-aventis U.S. LLC$160
  • Organogenesis Inc.$125
  • Axsome Therapeutics, Inc.$107
  • AbbVie$99
  • plus $626 from 17 others

What the payments were for

  • Food & beverage$1,93499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,954 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,643
Medicare patients
81
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$123,571
JardianceEmpagliflozin63$79,680
JanuviaSitagliptin Phosphate61$64,684
EliquisApixaban51$37,726
TrulicityDulaglutide32$37,267
XareltoRivaroxaban30$24,411
RybelsusSemaglutide16$20,301
InvokanaCanagliflozin20$17,093
EntrestoSacubitril/Valsartan15$15,302
Lantus SolostarInsulin Glargine,hum.Rec.Anlog109$14,353
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,135
TradjentaLinagliptin14$12,442
MounjaroTirzepatide12$11,879
LinzessLinaclotide15$11,442
FarxigaDapagliflozin Propanediol15$9,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$50$143,872154 claims
Boehringer IngelheimJardiance, Tradjenta$58$92,12277 claims
Lilly USA, LLCTrulicity, Mounjaro$498$49,14644 claims
PfizerEliquis$15$37,72651 claims
GSKTrelegy Ellipta, Breo Ellipta$19$18,85335 claims
AbbVieLinzess$99$11,44215 claims
Sanofi-aventis U.S. LLCLantus$160$1,63916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →